Bedaquiline in MDR/XDR-TB cases: First experience on compassionate use

European Respiratory Journal

Volumn 43, Issue 1, 2014, Pages 289-292

  Tiberi, Simon ^a   De Lorenzo, Saverio ^b   Centis, Rosella ^c   Viggiani, Pietro ^b   D'Ambrosio, Lia ^c   Migliori, Giovanni Battista ^c  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b Reference Hospital for MDR and HIV TB   (Italy)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BEDAQUILINE; CAPREOMYCIN; DIAZEPAM; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANXIETY DISORDER; ARTHRALGIA; COMPASSIONATE USE; DIARRHEA; DISTRIBUTION VOLUME; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEADACHE; HUMAN; LETTER; LUNG INFILTRATE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; SPUTUM CULTURE; SPUTUM SMEAR;

ADULT; AGED; ANTITUBERCULAR AGENTS; COMPASSIONATE USE TRIALS; DIARYLQUINOLINES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84891942518     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00122313     Document Type: Letter

References (10)

1. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: Individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
2. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: Impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
3. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
4. Diel R, Rutz S, Castell S, et al. Tuberculosis: Cost of illness in Germany. Eur Respir J 2012; 40: 143-151.
5. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
6. Migliori GB, Sotgiu G. Treatment of tuberculosis: Have we turned the corner Lancet 2012; 380: 955-957.
7. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem/clavunate added to linezolid containing regimens in the treatment of M/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
8. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrugresistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
9. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: Interim policy guidance. Document WHO/HTM/TB/2013.6. Geneva, World Health Organization, 2013.
10. Horsburgh CR Jr, Haxaire-Theeuwes M, Lienhardt C, et al. Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013; 17: 146-152.